

Anti-Inflammatory Therapy with Canakinumab for the Prevention and Management of Diabetes

Brendan M. Everett, MD, MPH, Marc Y. Donath, MD, Aruna D. Pradhan, MD, MPH, Tom Thuren, MD, Prem Pais, MD, Jose C. Nicolau, MD, Robert J. Glynn, ScD, Peter Libby, MD, Paul M. Ridker, MD, MPH

---

PII: S0735-1097(18)33483-1

DOI: [10.1016/j.jacc.2018.03.002](https://doi.org/10.1016/j.jacc.2018.03.002)

Reference: JAC 24732

To appear in: *Journal of the American College of Cardiology*

Received Date: 14 February 2018

Revised Date: 28 February 2018

Accepted Date: 1 March 2018

Please cite this article as: Everett BM, Donath MY, Pradhan AD, Thuren T, Pais P, Nicolau JC, Glynn RJ, Libby P, Ridker PM, Anti-Inflammatory Therapy with Canakinumab for the Prevention and Management of Diabetes, *Journal of the American College of Cardiology* (2018), doi: 10.1016/j.jacc.2018.03.002.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

## Anti-Inflammatory Therapy with Canakinumab for the Prevention and Management of Diabetes

Brendan M. Everett, MD, MPH,<sup>a,b</sup> Marc Y. Donath, MD,<sup>c</sup> Aruna D. Pradhan, MD, MPH,<sup>a,d</sup> Tom Thuren, MD,<sup>e</sup> Prem Pais, MD,<sup>f</sup> Jose C. Nicolau,<sup>g</sup> MD, Robert J. Glynn, ScD,<sup>a</sup> Peter Libby, MD,<sup>b</sup> Paul M Ridker, MD, MPH<sup>a,b</sup>

From the <sup>a</sup>Cardiovascular Disease Prevention and the <sup>b</sup>Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston; <sup>c</sup>Endocrinology, Diabetes & Metabolism, University Hospital Basel, Basel, Switzerland; <sup>d</sup>Division of Cardiovascular Medicine, Department of Medicine, VA Boston Medical Center, West Roxbury, Massachusetts; <sup>e</sup>Novartis, East Hanover, NJ, and Basel, Switzerland; <sup>f</sup>St. John's Research Institute, Bangalore, India; <sup>g</sup>Instituto do Coracao (InCor), Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil.

**Brief Title:** Canakinumab for Diabetes Prevention and Management

**Funding:** Funded by Novartis, Basel, Switzerland

**Disclosures:** PMR, RJG, PP, and JCN received research grant support from Novartis Pharmaceuticals to conduct the CANTOS trial. PMR, BME, and PL have served as consultants to Novartis and BME has grant support from Novartis for work unrelated to CANTOS. PMR is listed as a co-inventor on patents held by the Brigham and Women's Hospital that relate to the use of inflammatory biomarkers in cardiovascular disease and diabetes that have been licensed to AstraZeneca and Siemens. TT is an employee of, and holds stock in, Novartis Pharmaceuticals. All other authors declare no competing interests.

**Address for Correspondence:**

Brendan M. Everett, MD, MPH  
Brigham and Women's Hospital  
Divisions of Preventive and Cardiovascular Medicine  
900 Commonwealth Ave  
Boston, MA 02215  
Telephone: 857-307-1990  
Fax: 857-307-1955  
E-mail: [beverett@bwh.harvard.edu](mailto:beverett@bwh.harvard.edu)  
Twitter: [@brendan](https://twitter.com/brendan)

متن کامل مقاله

دریافت فوری ←

**ISI**Articles

مرجع مقالات تخصصی ایران

- ✓ امکان دانلود نسخه تمام متن مقالات انگلیسی
- ✓ امکان دانلود نسخه ترجمه شده مقالات
- ✓ پذیرش سفارش ترجمه تخصصی
- ✓ امکان جستجو در آرشیو جامعی از صدها موضوع و هزاران مقاله
- ✓ امکان دانلود رایگان ۲ صفحه اول هر مقاله
- ✓ امکان پرداخت اینترنتی با کلیه کارت های عضو شتاب
- ✓ دانلود فوری مقاله پس از پرداخت آنلاین
- ✓ پشتیبانی کامل خرید با بهره مندی از سیستم هوشمند رهگیری سفارشات